Stromal Vascular Fraction and Autologous Activated Platelet-Rich Plasma Combination in Treatment of Type 2 Diabetes: A Single Center Retrospective Study

Objective: A cutting edge potential treatment of type 2 diabetes (T2D) is the use of cellular therapy. One recent method is the use of combination of stromal vascular fraction (SVF) and autologous activated platelet-rich plasma (aaPRP). This study is aimed to evaluate the efficacy of SI/F combined with aaPRP to treat T2D. Materials and methods: Patients with T2D who un- derwent SI/F and aaPRP treatment were recruited in this study. The lipoaspirate was digested by H-Remedy enzyme and centrifuged to isolate SI/F. Blood was drawn from the patients and the aaPRP was isolated. The combination of autologous SI/F and aaPRP was administered intravenously to each patient. Patients' 1-month and 3-month post-therapy HbA1c level were statistically analyzed to their baseline level. Results: A total of 39 patients, 28 male and 11 female, with T2D with mean age of 59 & PLUSMN;11 years and baseline HbA1c of 8.31 g/dL were included in this study. Com- bination of SVF and aaPRP treatment in T2D resulted in a statistically significant decrease in HbA1c level to 7.58 g/dL at 1 month and to 7.63 g/dL at 3 months post -therapy, while a decrease in HbA1c was still observed at 6 and 12 months after therapy. Conclusions: SI/F combined with aaPRP may have potential to reduce HbA1c levels in patients with T2D. Further research is needed to confirm the findings of our research. (Clin Diabetol 2023; 12; 4: 247-252) Clinical trial registration number: NCT05925829